Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INFU NASDAQ:MGRM NASDAQ:OBIO NASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINFUInfuSystem$6.13-1.9%$5.83$4.61▼$9.97$128.83M1.81116,006 shs108,976 shsMGRMMonogram Orthopaedics$3.30+13.4%$2.73$1.92▼$4.21$103.85M0.59249,687 shs194,096 shsOBIOOrchestra BioMed$2.93+1.4%$2.94$2.37▼$8.87$110.72M0.61187,909 shs189,721 shsPYPDPolyPid$3.43-0.6%$3.12$2.30▼$4.42$35.16M1.32133,805 shs113,379 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINFUInfuSystem+1.46%+0.16%+2.29%+30.21%-8.49%MGRMMonogram Orthopaedics0.00%+0.69%+14.57%+21.76%+39.23%OBIOOrchestra BioMed-0.17%+7.84%-12.69%+3.58%-64.23%PYPDPolyPid-1.15%-2.27%+5.50%+40.59%-13.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINFUInfuSystem1.9205 of 5 stars2.02.00.00.00.04.21.9MGRMMonogram Orthopaedics2.3167 of 5 stars3.82.00.00.01.11.70.6OBIOOrchestra BioMed2.6282 of 5 stars3.65.00.00.00.81.70.0PYPDPolyPid2.0925 of 5 stars3.63.00.00.01.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINFUInfuSystem 4.00Strong Buy$13.00112.07% UpsideMGRMMonogram Orthopaedics 3.50Strong Buy$5.4063.64% UpsideOBIOOrchestra BioMed 3.20Buy$14.20384.64% UpsidePYPDPolyPid 3.17Buy$11.80244.02% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, INFU, OBIO, and MGRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINFUInfuSystem$137.58M0.94$0.48 per share12.79$2.47 per share2.48MGRMMonogram Orthopaedics$370K318.32N/AN/A$0.42 per share7.86OBIOOrchestra BioMed$2.64M42.52N/AN/A$0.87 per share3.37PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINFUInfuSystem$870K$0.14102.1819.77N/A1.12%2.78%1.41%N/AMGRMMonogram Orthopaedics-$16.33M-$0.45N/AN/AN/AN/A-115.71%-92.75%8/13/2025 (Estimated)OBIOOrchestra BioMed-$61.02M-$1.78N/AN/AN/A-2,297.85%-189.26%-93.76%N/APYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-1,069.37%-151.85%8/13/2025 (Estimated)Latest PYPD, INFU, OBIO, and MGRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MGRMMonogram Orthopaedics-$0.12-$0.10+$0.02-$0.10N/AN/A5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINFUInfuSystemN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINFUInfuSystem0.501.981.59MGRMMonogram OrthopaedicsN/A7.007.00OBIOOrchestra BioMed0.853.353.34PYPDPolyPid4.430.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINFUInfuSystem71.13%MGRMMonogram Orthopaedics0.45%OBIOOrchestra BioMed53.55%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipINFUInfuSystem11.40%MGRMMonogram Orthopaedics28.10%OBIOOrchestra BioMed8.10%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINFUInfuSystem41021.02 million19.10 millionOptionableMGRMMonogram Orthopaedics2835.69 million25.66 millionNot OptionableOBIOOrchestra BioMed438.31 million35.21 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataPYPD, INFU, OBIO, and MGRM HeadlinesRecent News About These CompaniesPolyPid Ltd. (PYPD) Latest Stock News & Headlines - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA ApprovalJune 18, 2025 | nasdaq.comPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsJune 16, 2025 | globenewswire.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comPolyPid reports positive phase 3 surgical infection drug trialJune 11, 2025 | en.globes.co.ilENano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100June 6, 2025 | quiverquant.comQPolyPid to Host Conference Call and Webcast to Discuss D-PLEXâ‚₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 6, 2025 | globenewswire.comRoth Capital Initiates Coverage of PolyPid (PYPD) with Buy RecommendationJune 6, 2025 | msn.comPolyPid at Lytham Partners: Strategic Advances and Financial StabilityMay 30, 2025 | investing.comPESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data ReadoutMay 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYPD, INFU, OBIO, and MGRM Company DescriptionsInfuSystem NYSE:INFU$6.13 -0.12 (-1.92%) As of 04:00 PM EasternInfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Monogram Orthopaedics NASDAQ:MGRM$3.30 +0.39 (+13.40%) Closing price 04:00 PM EasternExtended Trading$3.32 +0.03 (+0.76%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.Orchestra BioMed NASDAQ:OBIO$2.93 +0.04 (+1.38%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.02 (+0.68%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.PolyPid NASDAQ:PYPD$3.43 -0.02 (-0.58%) Closing price 04:00 PM EasternExtended Trading$3.44 +0.00 (+0.15%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
